2C-T-25
2C-T-25, also known as 4-isobutylthio-2,5-dimethoxyphenethylamine, is a serotonin receptor modulator of the phenethylamine and 2C families. It shows affinity for serotonin receptors and other targets and acts as a potency partial agonist of the serotonin 5-HT2A and 5-HT2B receptors. The dose of 2C-T-25 in humans is unknown. Daniel Trachsel reported that 2C-T-25 was inactive at doses of up to 30mg orally. The drug was first described in the scientific literature by Trachsel in 2003 and was subsequently described further by Trachsel and colleagues in 2013 and 2018. It is a controlled substance in Canada under phenethylamine blanket-ban language.